Pharmacogenetic Impact on Korean Patients Receiving Antiepileptic Drugs |
Kim, Jeong-Oh
(Laboratory of Medical Oncology, Research Institutes of Medical Science, College of Medicine, Catholic University)
Lee, Han-Hee (Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University) Shin, Jung-Young (Laboratory of Medical Oncology, Research Institutes of Medical Science, College of Medicine, Catholic University) Zhang, Xiang Hua (Laboratory of Medical Oncology, Research Institutes of Medical Science, College of Medicine, Catholic University) Oh, Ji-Eun (Laboratory of Medical Oncology, Research Institutes of Medical Science, College of Medicine, Catholic University) Kim, Yeong-In (Department of Neurology, College of Medicine, Catholic University) Lee, Jeong-Hyun (Laboratory of Medical Oncology, Research Institutes of Medical Science, College of Medicine, Catholic University) Kang, Jin-Hyoung (Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Catholic University) |
1 | Bae, J. W., Kim, H. K., Kim, J. H., Yang, S. I., Kim, M. J., Jang, C. G., Park, Y. S. and Lee, S. Y. 2005. Allele and genotype frequencies of CYP2C9 in a Korean population. Br. J. Clin. Pharmacol. 60, 418-422. DOI ScienceOn |
2 | Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y. and Chen, Y. T. 2004. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486. DOI ScienceOn |
3 | Escayg, A., Heils, A., MacDonald, B. T., Haug, K., Sander, T. and Meisler, M. H. 2001. A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus-and prevalence of variants in patients with epilepsy. Am. J. Hum. Genet. 68, 866-873. DOI |
4 | Gnerre, C., Blattler, S., Kaufmann, M. R., Looser, R. and Meyer, U. A. 2004. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14, 635-645. DOI |
5 | Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. and Brinkmann, U. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478. DOI |
6 | Ho, P. C., Abbott, F. S., Zanger, U. M. and Chang, T. K. 2003. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 3, 335-342. DOI |
7 | Ibeanu, G. C., Blaisdell, J., Ghanayem, B. I., Beyeler, C., Benhamou, S., Bouchardy, C., Wilkinson, G. R., Dayer, P., Daly, A. K. and Goldstein, J. A. 1998. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 8, 129-135. DOI |
8 | Ibeanu, G. C., Goldstein, J. A., Meyer, U., Benhamou, S., Bouchardy, C., Dayer, P., Ghanayem, B. I. and Blaisdell, J. 1998. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther. 286, 1490-1495. |
9 | Kidd, R. S., Straughn, A. B., Meyer, M. C., Blaisdell, J., Goldstein, J. A. and Dalton, J. T. 1999. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 9, 71-80. DOI ScienceOn |
10 | Kim, K. A., Song, W. K., Kim, K. R. and Park, J. Y. 2010. Assessment of CYP2C19 genetic polymorphisms in a korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. J. Clin. Pharm. Ther. 35, 697-703. DOI |
11 | Loscher, W., Klotz, U., Zimprich, F. and Schmidt, D. 2009. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50, 1-23. |
12 | Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Bosquski, M, S. and Schuetz, E. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391. DOI |
13 | Kwan, P. and Brodie, M. J. 2001. Effectiveness of first antiepileptic drug. Epilepsia 42, 1255-1260. DOI |
14 | Lee, S. S., Kim, S. Y., Kim, W. Y., Thi-Le, H., Yoon, Y. R., Yea, S. S. and Shin, J. G. 2005. MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. Ther. Drug. Monit. 27, 531-535. DOI |
15 | Mamiya, K., Ieiri, I., Shimamoto, J., Yukawa, E., Imai, J., Ninomiya, H., Yamada, H., Otsubo, K., Higuchi, S. and Tashiro, N. 1998. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 39, 1317-1323. DOI ScienceOn |
16 | Pirmohamed, M., Lin, K., Chadwick, D. and Park, B. K. 2001. TNFalpha promotor region gene polymorphisms in carbamazepine hypersensitive patients. Neurology 56, 890-896. DOI |
17 | Plant, N. J. and Gibson, G. G. 2003. Evaluation of the toxicological relevance of CYP3A4 induction. Curr. Opin. Drug. Discov. Devel. 6, 50-56. |
18 | Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B., Wood, N. W. and Sisodiva, S. M. 2003. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442-1448. DOI |
19 | Tan, N. C., Heron, S. E., Scheffer, I. E., Pelekanos, J. T., McMahon, J. M., Vears, D. F., Mulley, J. C. and Berkovic, S. F. 2004. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63, 1090-1092. DOI ScienceOn |
20 | Sillanpaa, M. and Schmidt, D. 2006. Natural history of treated childhood onset epilepsy: prospective, long-term population- based study. Brain 129, 617-624. DOI ScienceOn |
21 | Tan, N. C., Mulley, J. C. and Berkovic, S. F. 2004. Genetic association studies in epilepsy: "the truth is out there". Epilepsia 45, 1429-442. DOI |
22 | Tate, S. K., Depondt, C., Sisodiya, S. M., Cavalleri, G. L., Schorge, S., Soranzo, N., Thom, M., Sen, A., Shorvon, S. D., Sander, J. W., Wood, N. W. and Goldstein, D. B. 2005. Genetic predictors of the maximum doses patients receive during clinical use of the antiepileptic drugs carbamazepine and phenytoin. Proc. Natl. Acad. Sci. USA 102, 5507-5512. DOI |
23 | Zhu, B., Chen, G. L., Chen, X. P., He, N., Liu, Z. Q., Jiang, C. H., Wang, D. and Zhou, H. H. 2002. Genotype of CYP3AP1 associated with CYP3A activity in Chinese Han population. Acta. Pharmacol. Sin. 23, 567-572. |
24 | Zimprich, F., Sunder-Plassmann, R., Stogmann, E., Gleiss, A., Dal-Blanco, A., Zimprich, A., Plumer, S., Baumgartner, C. and Mannhalter, C. 2004. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63, 1087-1089. DOI ScienceOn |
25 | Vajda, F. J. 2007. Pharmacotherapy of epilepsy: new armamentarium, new issues. J. Clin. Neurosci. 14, 813-823. DOI |